PMID- 29758547
OWN - NLM
STAT- MEDLINE
DCOM- 20190813
LR  - 20190813
IS  - 1878-5905 (Electronic)
IS  - 0142-9612 (Linking)
VI  - 173
DP  - 2018 Aug
TI  - Ultrasound assisted gene and photodynamic synergistic therapy with 
      multifunctional FOXA1-siRNA loaded porphyrin microbubbles for enhancing 
      therapeutic efficacy for breast cancer.
PG  - 58-70
LID - S0142-9612(18)30326-0 [pii]
LID - 10.1016/j.biomaterials.2018.04.054 [doi]
AB  - To improve the non-invasive therapeutic efficacy for ER positive breast cancer 
      (ER+ BC), we fabricated a multifunctional FOXA1 loaded porphyrin microbubble to 
      combine photodynamic therapy (PDT) and gene therapy of FOXA1 knockdown (KD) with 
      ultrasound targeted microbubble destruction (UTMD) technology under the guidance 
      of contrast enhanced ultrasound (CEUS). Cationic porphyrin microbubbles (CpMBs) 
      were firstly fabricated from a porphyrin grafted lipid with two cationic amino 
      groups (PGL-NH2) and fluorocarbon inert gas of C(3)F(8). Porphyrin group in the 
      CpMBs monolayer could be used as a photosensitizer for PDT, while amino groups 
      could adsorb siRNA through electrostatic interaction for FOXA1 KD, which could 
      inhibit the proliferation of estrogen-dependent ER+ BC. This system showed high 
      photosensitizer and gene loading content. Moreover, CpMBs/siRNA can be converted 
      into nanoparticles with low-frequency pulsed ultrasound (LFUS) exposure, which 
      increase the transfection efficiency of siRNA ( approximately 4 fold) and the porphyrin uptake 
      ( approximately 8 fold) in MCF-7 (a human breast cancer cell line, ER+) by sonoporation effect. 
      In vivo, UTMD was performed under the guidance of CEUS, and the fluorescence 
      intensity of CpMBs/siRNA at the tumour site reached a peak value at 6 h after 
      injection and it was retained in the following 24 h. Furthermore, there was no 
      tumour recurrence during the observation period (21 days) in the group of PDT 
      combined with FXOA1 KD. Compared to the PDT or FOXA1 KD alone group, the 
      combination of these two methods was much more efficient in inhibiting ER+ breast 
      cancer, showing a good synergistic effect. CpMBs/siRNA combined with UTMD 
      dramatically increased the local accumulation of porphyrin and siRNA through 
      ultrasound-induced sonoporation effect under the guidance of CEUS, showing 
      excellent therapeutic effect for estrogen-dependent ER+ breast cancer.
CI  - Copyright (c) 2018 Elsevier Ltd. All rights reserved.
FAU - Zhao, Ranran
AU  - Zhao R
AD  - Department of Ultrasound, Peking University Third Hospital, Beijing 100191, 
      China; Ordos Center Hospital, Ordos, Inner Mongolia 017000, China.
FAU - Liang, Xiaolong
AU  - Liang X
AD  - Department of Ultrasound, Peking University Third Hospital, Beijing 100191, 
      China.
FAU - Zhao, Bo
AU  - Zhao B
AD  - Department of Ultrasound, Peking University Third Hospital, Beijing 100191, 
      China.
FAU - Chen, Min
AU  - Chen M
AD  - Department of Biomedical Engineering, College of Engineering, Peking University, 
      Beijing 10019, China.
FAU - Liu, Renfa
AU  - Liu R
AD  - Department of Biomedical Engineering, College of Engineering, Peking University, 
      Beijing 10019, China.
FAU - Sun, Sujuan
AU  - Sun S
AD  - Ordos Center Hospital, Ordos, Inner Mongolia 017000, China.
FAU - Yue, Xiuli
AU  - Yue X
AD  - School of Environment, Harbin Institute of Technology, Harbin 150080, China. 
      Electronic address: xiulidx@163.com.
FAU - Wang, Shumin
AU  - Wang S
AD  - Department of Ultrasound, Peking University Third Hospital, Beijing 100191, 
      China; Ordos Center Hospital, Ordos, Inner Mongolia 017000, China. Electronic 
      address: shuminwang2014@163.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180503
PL  - Netherlands
TA  - Biomaterials
JT  - Biomaterials
JID - 8100316
RN  - 0 (FOXA1 protein, human)
RN  - 0 (Hepatocyte Nuclear Factor 3-alpha)
RN  - 0 (Lipids)
RN  - 0 (Photosensitizing Agents)
RN  - 0 (Porphyrins)
RN  - 0 (RNA, Small Interfering)
RN  - U6F3787206 (Aminocaproic Acid)
MH  - Aminocaproic Acid/chemistry
MH  - Animals
MH  - Apoptosis
MH  - Breast Neoplasms/*therapy
MH  - Combined Modality Therapy
MH  - Female
MH  - Genetic Therapy/*methods
MH  - Hepatocyte Nuclear Factor 3-alpha/*genetics
MH  - Heterografts
MH  - Humans
MH  - Lipids/chemistry
MH  - MCF-7 Cells
MH  - Mice, Inbred BALB C
MH  - Mice, Nude
MH  - Microbubbles
MH  - Nanoparticles/chemistry
MH  - Photochemotherapy/*methods
MH  - Photosensitizing Agents/chemistry
MH  - Porphyrins/*chemistry
MH  - RNA, Small Interfering/*chemistry/genetics
MH  - Static Electricity
MH  - *Ultrasonic Waves
OTO - NOTNLM
OT  - Breast cancer
OT  - Cationic porphyrin
OT  - Photodynamic therapy
OT  - RNA interference
OT  - Ultrasound
EDAT- 2018/05/15 06:00
MHDA- 2019/08/14 06:00
CRDT- 2018/05/15 06:00
PHST- 2018/01/16 00:00 [received]
PHST- 2018/04/29 00:00 [revised]
PHST- 2018/04/30 00:00 [accepted]
PHST- 2018/05/15 06:00 [pubmed]
PHST- 2019/08/14 06:00 [medline]
PHST- 2018/05/15 06:00 [entrez]
AID - S0142-9612(18)30326-0 [pii]
AID - 10.1016/j.biomaterials.2018.04.054 [doi]
PST - ppublish
SO  - Biomaterials. 2018 Aug;173:58-70. doi: 10.1016/j.biomaterials.2018.04.054. Epub 
      2018 May 3.